Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Atara Biotherap (NQ: ATRA)
42.97 USD  +2.77 (+6.89%)
Official Closing Price  /  Updated: 5:24 PM EST, Dec 10, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 599,824
Open 40.50
Bid (Size) 41.03 (1)
Ask (Size) 44.50 (6)
Prev. Close 40.20
Today's Range 40.00 - 43.22
52wk Range 14.31 - 54.45
Shares Outstanding 43,949,486
Dividend Yield N/A
Performance
YTD
+137.40%
+137.40%
1 Month
+18.60%
+18.60%
3 Month
+8.10%
+8.10%
6 Month
+0.28%
+0.28%
1 Year
+196.34%
+196.34%
Top News
More News
Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) An
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today... Read More
from GlobeNewswire News Releases
Atara Biotherapeutics Highlights Next-Generation and Off-the-Shelf, Allogeneic CAR T Technologies and Pipeline
Atara has assembled core technologies and capabilities to develop next-generation and off-the-shelf, allogeneic CAR T immunotherapies, collaborating with academic leaders as well as leveraging the... Read More
from GlobeNewswire News Releases
More News
Read More
Atara Biotherapeutics to Host CAR T Breakfast Teach-In on November 29, 2018
from GlobeNewswire News Releases
Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus (EBV)-S
from GlobeNewswire News Releases
Atara Biotherapeutics Announces Third Quarter 2018 Financial Results and Recent Operational Progress
from GlobeNewswire News Releases
Atara Biotherapeutics Announces Presentations Highlighting Robust Off-the-Shelf, Allogeneic T-Cell Immunotherapy Pipeline and Next-Generation CAR T Technologies at the 60th American Society of Hemato
from GlobeNewswire News Releases
Report: Exploring Fundamental Drivers Behind Monroe Capital, Anavex Life Sciences, Haynes International, Atara Biotherapeutics, Lands' End, and Envestnet — New Horizons, Emerging Trends, and Upcoming
from GlobeNewswire News Releases
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
from GlobeNewswire News Releases
Atara Biotherapeutics Appoints Cancer Research and Clinical Development Veteran, Roy Baynes, to its Board of Directors
from GlobeNewswire News Releases
Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies
from GlobeNewswire News Releases
ATRA Makes Bullish Cross Above Critical Moving Average
category Stocks
from Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.